Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioLine Rx's Revenue for the
three
months ended in Mar. 2026 was $0.48 Mil. BioLine Rx's Total Assets for the quarter that ended in Mar. 2026 was $39.85 Mil. Therefore, BioLine Rx's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.
Asset Turnover is linked to ROE % through Du Pont Formula. BioLine Rx's annualizedROE % for the quarter that ended in Mar. 2026 was -36.73%. It is also linked to ROA % through Du Pont Formula. BioLine Rx's annualizedROA % for the quarter that ended in Mar. 2026 was -16.07%.
BioLine Rx (NAS:BLRX) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
BioLine Rx's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
BioLine Rx's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
BioLine Rx Asset Turnover Related Terms
BioLine Rx Asset Turnover Historical Data
* Premium members only.
The historical data trend for BioLine Rx's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLRX vs VRTX, REGN, ALNY: Asset Turnover Comparison
For the Biotechnology subindustry, BioLine Rx's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Asset Turnover distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
BioLine Rx (BLRX) has a Asset Turnover of 0.01 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Asset Turnover too high?
BioLine Rx's current Asset Turnover is 0.01. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Asset Turnover compare to VRTX and REGN?
BioLine Rx's Asset Turnover of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on BioLine Rx and its competitors. BioLine Rx's current Asset Turnover is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current Asset Turnover of 0.01. The current Asset Turnover is 0.01. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For BioLine Rx (BLRX), the current Asset Turnover is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score
Get the complete analysis for BLRX
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLRX has been successfully added to your 
